Abstract: This invention relates to chiral compositions.

Abstract: This disclosure relates to the aspermatogenesis activity of compounds of the following formula: ##STR1## where R.sub.1 and R.sub.2 each independently represent hydrogen, halo having an atomic weight of about 19 to 36, lower alkyl having 1 to 4 carbon atoms, lower alkoxy having 1 to 4 carbon atoms, trifluoromethyl, orR.sub.1 is ##STR2## and R.sub.2 is hydrogen, whereinR.sub.7 and R.sub.8 are each independently hydrogen or lower alkyl having 1 to 2 carbon atoms,n is 0 or 1, andR.sub.3, R.sub.4, R.sub.5 and R.sub.6 each independently represent lower alkyl having 1 to 2 carbon atoms ora pharmaceutically acceptable salt thereof.

Abstract: Sulfur and silicon-containing amides, e.g. N-5-sila-3-thia-5,5-dimethyl-pentadecanoyl-1-phenyl-2-(4-methylphenyl)-eth ylamine, are useful as anti-atherosclerotic agents. The amides are obtainable by acylation of a primary amine (the substituents on the amine being of the aralkyl phenyl, tryptophanyl, benzocycloalkyl-type) with a corresponding sulfur and silicon-containing carboxylic acid (or active form thereof).

Abstract: Compounds of the formula ##STR1## in which R.sup.1 is a mono-silicon-containing hydrocarbyl radical having up to 35 carbon atoms;each of R.sup.2 and R.sup.3 is, independently, a hydrogen atom or lower alkyl having from 1 to 3 carbon atoms;n is 0 or 1; andM is a hydrogen atom, an equivalent of a cation which forms a non-toxic, pharmaceutically acceptable salt, or a non-toxic pharmaceutically acceptable monovalent radical which is hydrolyzable or saponifiable to an alkali metal cation, eg sodium 4-(4,4-dimethyl-4-sila-tetradecylamino)-benzoate, are useful as pharmaceutical agents.

Abstract: Silicon-containing amides, e.g., N-[1'-phenyl-2'-(4"-methylphenyl)ethyl]-2,2,6,6-tetramethyl-1-oxa-2,6-disi lacyclohexane-4-carboxamide, are useful as anti-atherosclerotic agents. The amides are obtainable by acylation of a primary amine (the substituents on the amine being of the aralkyl phenyl, tryptophanyl, benzocycloalkyl-type) with a corresponding silicon-containing carboxylic acid (or active form thereof).

Abstract: This disclosure describes compounds of the formula ##STR1## wherein n is 3, 5 or 7, andeach R is lower alkyl having 1 to 4 carbon atoms, or pharmaceutically acceptable acid addition salts thereof, which are useful as anti-diabetic agents in particular glucagon inhibiting agents.

Abstract: The final products are compounds of the formula ##STR1## wherein (a) each of R.sup.1, R.sup.2 and R.sup.3 alkyl having from 1 to 22 carbon atoms; or(b) one or more is a phenyl or alkylphenyl type, n is from 3 to 20; andR is of an aralkyl-, phenyl-tryptophanyl- or benzocycloalkyl-type, eg D,L-5,5-dimethyl-5-sila-pentadecanoyl-1'-phenyl-2'-p-tolyl-ethylamide, are useful as antiatherosclerotic agents, and are prepared from corresponding carboxylic acids (or their derivatives).

Abstract: This disclosure describes compounds of the formula ##STR1## wherein R.sub.1 represents ##STR2## and R.sub.2, R.sub.3, R.sub.4 and R.sub.5 each independently represent lower alkyl having 1 to 2 carbon atoms, andn is 1 or 2,which are useful as muscle-relaxant agents.

Abstract: This disclosure describes novel compounds of the formula: ##STR1## where R.sub.1 and R.sub.2 each independently represent hydrogen, halo having an atomic weight of about 19 to 36, lower alkyl, lower alkoxy,trifluoromethyl or R.sub.1 is ##STR2## and R.sub.2 is hydrogen, whereinR.sub.7 and R.sub.8 are each independently hydrogen or lower alkyl andn is 0 or 1, andR.sub.3, R.sub.4, R.sub.5 and R.sub.6 each independently represent lower alkyl, which are useful as muscle relaxants.

Abstract: Compounds of the following structure ##STR1## where R.sub.1 represents H or alkyl having 1-5 carbon atoms,R.sub.2, R.sub.3, R.sub.4 and R.sub.5 each, independently represents H or alkyl having 1-2 carbon atomsR.sub.6 represents H, alkyl having 1-5 carbon atoms, halo, alkoxy having 1-5 carbon atoms or ##STR2## where R.sub.8 and R.sub.9 each, independently, represent alkyl having 1-2 carbon atoms, andR.sub.7 represents alkyl having 1-5 carbon atoms,e.g., 1-(p-chlorophenyl)-1,4-dihydro-.beta.,.beta.,1-trimethyl-3,1-benzazasiline -3(2H)-ethanol, are prepared from corresponding oxazolo benzazasilanes by reduction with borohydride, and are useful as sleep inducers.

Abstract: Benzazasilin-4-ones of the formula ##STR1## where R.sub.1 represents H or alkyl of 1-5 carbon atoms,R.sub.2 represents alkyl of 1-5 carbon atoms,R.sub.3 represents alkyl of 1-5 carbon atoms or ##STR2## where R.sub.5 represents H, alkyl of 1-5 carbon atoms, halo having an atomic weight of about 19-36, alkoxy having 1-5 carbon atoms, or ##STR3## where R.sub.6 and R.sub.7 each, independently, represent alkyl having 1-2 carbon atoms, andR.sub.4 represents alkyl having 1-3 carbon atoms, e.g., 1-(p-chlorophenyl)-2,3-dihydro-1,3-dimethyl-3,1-benzazasilin-4(1H)-one, are prepared from the appropriate lithiated N-alkyl benzamide and a halomethyl halosilane and are useful as antiobesity agents or sleep inducers.

Abstract: 2,4-Disubstituted-4b,5,6,7,8,8a,9,10-octahydro-9-oxo-phenanthrenes e.g., 2,4-dimethoxy-4b,5,6,7,8,8a,9,10-octahydro-9-oxo-phenanthrene are useful as hypolipidemic agents.

Abstract: 2,4-Disubstituted-4b,5,6,7,8,8a,9,10-octahydro-9-oxo-phenanthrenes e.g., 2,4-dimethoxy-4b,5,6,7,8,8a,9,10-octahydro-9-oxo-phenanthrene are useful as hypolipidemic agents.

Abstract: 1-succinoyl-2,4-disubstituted-4b,5,6,7,8,8a,9,10-octahydro-9-oxo-phenanthre nes, e.g., 1-succinoyl-2,4-dimethoxy-4b,5,6,7,8,8a,9,10-octahydro-9-oxo-phenanthrene are prepared by treating a corresponding 2,4-dimethoxy-4b,5,6,7,8,8a,9,10-octahydro-9-oxo-phenanthrene with a Friedel Crafts catalyst in the presence of an organic solvent, and are useful as hypolipidemic agents.